John C Molina
Overview
Explore the profile of John C Molina including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
158
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stewart B, Carraway H, Alvarez A, Lesmana H, Molina J, Tu Z, et al.
Blood Adv
. 2024 Dec;
PMID: 39657124
The Janus kinase 2 (JAK2) V617F mutation activates the transcription pathway and has been well-characterized as a driver of myeloproliferative neoplasms (MPNs). Recently, there has been a heightened interest in...
2.
3.
Molina J, Carraway H
Curr Treat Options Oncol
. 2024 Jun;
25(8):993-1010.
PMID: 38916714
For adult patients diagnosed with relapsed B cell-ALL (B-ALL), there have been significant improvements in available treatment options following the FDA approval of novel cellular and immunotherapy approaches - blinatumomab,...
4.
Molina J, Rotz S
Hematology Am Soc Hematol Educ Program
. 2023 Dec;
2023(1):573-580.
PMID: 38066875
Significant improvements have occurred for adolescent and young adult (AYA) B-cell acute lymphoblastic leukemia (B-ALL) patients following the widespread adoption of "pediatric-inspired" treatment regimens for AYA patients cared for in...
5.
Moerdler S, DuVall A, Hayes-Lattin B, Grimes A, Prasad P, Molina J, et al.
J Adolesc Young Adult Oncol
. 2023 Jul;
13(1):97-104.
PMID: 37477884
Adolescents and young adults (AYAs, 15-39 years) with cancer experience disparities in care and outcomes compared with older/younger patients. AYAs receive care from medical and pediatric oncologists, however, little is...
6.
Ogbue O, Unlu S, Ibodeng G, Singh A, Durmaz A, Visconte V, et al.
Cancers (Basel)
. 2023 May;
15(9).
PMID: 37173944
Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is...
7.
Molina J, Li Y, Otto W, Miller T, Getz K, Mccoubrey C, et al.
Pediatr Blood Cancer
. 2022 Nov;
70(1):e30062.
PMID: 36370087
Background: An adequate absolute lymphocyte count (ALC) is an essential first step in autologous chimeric antigen receptor (CAR) T-cell manufacturing. For patients with acute myelogenous leukemia (AML), the intensity of...
8.
Shalabi H, Qin H, Su A, Yates B, Wolters P, Steinberg S, et al.
Blood
. 2022 May;
140(5):451-463.
PMID: 35605184
Remission durability following single-antigen targeted chimeric antigen receptor (CAR) T-cells is limited by antigen modulation, which may be overcome with combinatorial targeting. Building upon our experiences targeting CD19 and CD22...
9.
Holland E, Molina J, Dede K, Moyer D, Zhou T, Yuan C, et al.
J Immunother Cancer
. 2022 May;
10(5).
PMID: 35534047
Chimeric antigen receptor T-cells (CART) are active in relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL), but relapse remains a substantial challenge. Reinfusion with the same CART product (CART2) in patients...
10.
Holland E, Yates B, Ling A, Yuan C, Wang H, Stetler-Stevenson M, et al.
Blood Adv
. 2021 Dec;
6(7):2167-2182.
PMID: 34920453
Chimeric antigen receptor (CAR) T cells effectively eradicate medullary B-cell acute lymphoblastic leukemia (B-ALL) and can traffic to and clear central nervous system (CNS) involvement. CAR T-cell activity in non-CNS...